Interestingly, resistance to Temozolomide (TMZ), an anti-tumor pharmaceutical studied for treating gliomas, is influenced by Cx43 expression and correlates with mitochondrial alterations including release of CytC and increased Bcl-2/Bax ratios. The gene discussed is BCL2; the disease is glioma.